NASH Treatment

In 5–15% of cases, nonalcoholic steatohepatitis (NASH), a more severe form of nonalcoholic fatty liver disease (NAFLD), can advance to cirrhosis and hepatocellular carcinoma. Within the next ten years, it is expected to rise to the top spot as the primary cause of end-stage liver disease and the most common reason for liver transplantation. Because it is closely linked to obesity, diabetes, and metabolic syndrome, non-alcoholic steatohepatitis (NASH) is the primary cause of chronic liver disease and a significant health issue in the Western world. Cell damage, inflammation, hepatocyte ballooning, different degrees of fibrosis, and cirrhosis are its defining features. These factors raise the risk of hepatocellular carcinoma (HCC), which has a high fatality rate. Check our NAFLD drug development